18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)

European Journal of Cancer

Volumn 39, Issue 14, 2003, Pages 2012-2020

  Stroobants, S ^a   Goeminne, J ^a   Seegers, M ^a   Dimitrijevic, S ^b   Dupont, P ^a   Nuyts, J ^a   Martens, M ^a   Van Den Borne, B ^a   Cole, P ^b   Sciot, R ^a   Dumez, H ^a   Silberman, S ^b   Mortelmans, L ^a   Van Oosterom, A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

c kit; Fluorodeoxyglucose; Gastrointestinal stromal tumour; Imatinib mesylate; Positron emission tomography; Receptor protein tyrosine kinase; Soft tissue sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; EVALUATION; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GASTROINTESTINAL TUMOR; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; SARCOMA; SCINTISCANNING; SURVIVAL; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; RADIOPHARMACEUTICALS; SARCOMA; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT FAILURE;

EID: 0041984595     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00073-X     Document Type: Article

References (27)

1. Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 48. 1979;World Health Organization, Geneva, Switzerland.
2. Therasse P., Arbuck S.G., Eisenhauer E.A.et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:2000;205-216.
3. Pauwels E.K., McCready V.R., Stoot J.H.et al. The mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur. J. Nucl. Med. 25:1998;277-305.
4. Bomanji J.B., Costa D.C., Ell P.J. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2:2001;157-164.
5. Hustinx R., Benard F., Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin. Nucl. Med. 32:2002;35-46.
6. Wahl R.L., Zasadny K., Helvie M.et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography. initial evaluation J. Clin. Oncol. 11:1993;2101-2111.
7. Schelling M., Avril N., Nahrig J.et al. Positron emission tomography using Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 18:2000;1689-1695.
8. Smith I.C., Welch A.E., Hutcheon A.W.et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J. Clin. Oncol. 18:2000;1676-1688.
9. Romer W., Hanauske A.R., Ziegler S.et al. Positron emission tomography in non-Hodgkin's lymphoma. assessment of chemotherapy with fluorodeoxyglucose Blood. 91:1998;4464-4471.
10. Brucher B.L., Weber W., Bauer M.et al. Neoadjuvant therapy of esophageal squamous cell carcinoma. response evaluation by positron emission tomography Ann. Surg. 233:2001;300-309.
11. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R.et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer. a prospective pilot study. The Leuven Lung Cancer Group Ann. Oncol. 9:1998;1193-1198.
12. Weihrauch M.R., Re D., Scheidhauer K.et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 98:2001;2930-2934.
13. Higashi K., Clavo A.L., Wahl R.L. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J. Nucl. Med. 34:1993;414-419.
14. Minn H., Joensuu H., Ahonen A.et al. Fluorodeoxyglucose imaging. a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors Cancer. 61:1988;1776-1781.
15. Young H., Baum R., Cremerius U.et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography. review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur. J. Cancer. 35:1999;1773-1782.
16. Buchdunger E., Cioffi C.L., Law N.et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:2000;139-145.
17. Rubin B.P., Singer S., Tsao C.et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121.
18. Singer S., Rubin B.P., Lux M.L.et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 20:2002;3898-3905.
19. Joensuu H., Roberts P.J., Sarlomo-Rikala Met al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:2001;1052-1056.
20. van Oosterom A.T., Judson I., Verweij J.et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours. a phase I study Lancet. 358:2001;1421-1423.
21. Demetri G.D., von Mehren M., Blanke C.D.et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480.
22. Shepp L., Vardi L. Maximum likelihood reconstruction for emission tomography. IEEE Trans. Med. Imag. 1:1982;113-122.
23. Hoekstra C.J., Hoekstra O.S., Stroobants S.G.et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J. Nucl. Med. 43:2002;1304-1309.
24. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol. Ther. 82:1999;231-239.
25. Folpe A.L., Lyles R.H., Sprouse J.T.et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin. Cancer Res. 6:2000;1279-1287.
26. Van den Abbeele AD, for GIST Collaborative PET Study Group. F18-FDG-PET provides early evidence of biological responses to STI571 in patients with malignant gastrointestinal stromal tumours. ASCO, 2001 (abstr 1444).
27. Boren J., Cascante M., Marin S.et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J. Biol. Chem. 276:2001;37747- 37753.